Fischer Joachim E, Steiner Felicitas, Zucol Franziska, Berger Christoph, Martignon Laura, Bossart Walter, Altwegg Martin, Nadal David
Division of Infectious Diseases, University Children's Hospital of Zurich, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland.
Arch Pediatr Adolesc Med. 2002 Oct;156(10):1005-8. doi: 10.1001/archpedi.156.10.1005.
Macrolides are the first-line antibiotic treatment of community-acquired pneumonia (CAP). Owing to alarming resistance rates among invasive Streptococcus pneumoniae isolates, particularly in young children, macrolide use should be restricted to patients infected with susceptible pathogens, eg, Mycoplasma pneumoniae.
To develop a simple clinical prediction rule for identifying M pneumoniae as the cause of CAP in children.
Prospective cohort study in 253 children with radiologically confirmed CAP in a walk-in clinic of a tertiary care hospital.
Mycoplasma infection, proven by results of antibody testing of paired serum samples (gold standard). We compared the area under the receiver operating characteristic curve (c statistic) of the following 2 prediction models: a scoring system derived from logistic regression analysis and a fast-and-frugal decision tree.
Mycoplasma pneumoniae infection was confirmed in 32 (13%) of 253 children. A scoring system based on duration of fever and patient age yielded a c statistic of 0.84 (95% confidence interval [CI], 0.77-0.91), compared with that of the decision tree (c = 0.76 [95% CI, 0.70-0.83]). The scoring system identified 75% of all cases as being at high or very high risk for M pneumoniae infection; the decision tree, 72% at high risk. The scoring system would curtail macrolide prescriptions by 75%; the decision tree, by 68%.
In children with CAP, simple clinical decision rules identify patients at risk for M pneumoniae infection. At present US macrolide resistance rates among invasive S pneumoniae isolates, both rules increase the chance of prescribing effective first-line antibiotics compared with general macrolide administration.
大环内酯类药物是社区获得性肺炎(CAP)的一线抗生素治疗药物。由于侵袭性肺炎链球菌分离株的耐药率令人担忧,尤其是在幼儿中,大环内酯类药物的使用应仅限于感染敏感病原体(如肺炎支原体)的患者。
制定一种简单的临床预测规则,以确定肺炎支原体是否为儿童CAP的病因。
在一家三级护理医院的门诊对253例经放射学确诊为CAP的儿童进行前瞻性队列研究。
通过配对血清样本抗体检测结果证实的支原体感染(金标准)。我们比较了以下两种预测模型的受试者工作特征曲线下面积(c统计量):一种基于逻辑回归分析得出的评分系统和一个快速节俭决策树。
253例儿童中有32例(13%)确诊为肺炎支原体感染。基于发热持续时间和患者年龄的评分系统的c统计量为0.84(95%置信区间[CI],0.77 - 0.91),而决策树的c统计量为0.76(95%CI,0.70 - 0.83)。评分系统将所有病例中的75%识别为肺炎支原体感染的高风险或极高风险;决策树则为72%的高风险。评分系统可减少75%的大环内酯类药物处方;决策树可减少68%。
在患有CAP的儿童中,简单的临床决策规则可识别出肺炎支原体感染风险较高的患者。按照目前美国侵袭性肺炎链球菌分离株的大环内酯类药物耐药率,与常规使用大环内酯类药物相比,这两种规则都增加了开具有效一线抗生素的机会。